Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6379-6386

  Miller, Joanna L ^a   Lachica, Ruben ^b   Sayce, Andrew C ^a   Williams, James P ^a   Bapat, Manisha ^a   Dwek, Raymond ^a   Beatty, P Robert ^c   Harris, Eva ^b   Zitzmann, Nicole ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Berkeley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMINOSUGAR; LIPOSOME; N (9 METHOXYNONYL)DEOXYNOJIRIMYCIN; N [6' (4'' AZIDO 2'' NITROPHENYLAMINO)HEXYL] 1 DEOXYNOJIRIMYCIN; N BUTYL DEOXYNOJIRIMYCIN; N NONYL DEOXYNOJIRIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; VIRUS LOAD;

1-DEOXYNOJIRIMYCIN; ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; DENGUE; DENGUE VIRUS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE DOSAGE; HUMANS; IMINO SUGARS; LIPOSOMES; MACROPHAGES; MICE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 84869231440     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01554-12     Document Type: Article

References (47)

1. Ardes-Guisot N, et al. 2011. Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain. Org. Biomol. Chem. 9:5373-5388.
2. Balsitis SJ, et al. 2009. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am. J. Trop. Med. Hyg. 80:416-424.
3. Balsitis SJ, et al. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6:e1000790. doi:10.1371/journal.ppat.1000790.
4. Bosch I, et al. 2002. Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J. Virol. 76:5588-5597.
5. Carr JM, et al. 2003. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J. Med. Virol. 69:521-528.
6. Ceballos-Olvera I, Chavez-Salinas S, Medina F, Ludert JE, del Angel RM. 2010. JNK phosphorylation, induced during dengue virus infection, is important for viral infection and requires the presence of cholesterol. Virology 396:30-36.
7. Chang J, et al. 2011. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 89:26-34.
8. Chang J, et al. 2011. Competitive inhibitor of cellular alpha-glucosidases protects mice from lethal dengue virus infection. Antiviral Res. 92:369-371.
9. Chang J, et al. 2009. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 53:1501-1508.
10. Cook CS, Karabatsos PJ, Schoenhard GL, Karim A. 1995. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharm. Res. 12:1158-1164.
11. Dejnirattisai W, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
12. Durbin AP, et al. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429-435.
13. Fink K, et al. 2009. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur. J. Immunol. 39:2809-2821.
14. Fischl MA, et al. 1994. The safety and efficacy of combination N-butyldeoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J. Acquir. Immune Defic. Syndr. 7:139-147.
15. Fox A, et al. 2011. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl. Trop. Dis. 5:e967. doi:10.1371/journal.pntd.0000967.
16. Gu B, et al. 2007. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 18:49-59.
17. Halstead SB. 1989. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis. 11(Suppl 4):S830-S839.
18. Halstead SB. 1980. Dengue haemorrhagic fever - a public health problem and a field for research. Bull. World Health Organ. 58:1-21.
19. James S, Simmons CP, James AA. 2011. Ecology. Mosquito trials. Science 334:771-772.
20. Klibanov AL, Maruyama K, Torchilin VP, Huang L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235-237.
21. Kou Z, et al. 2008. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80:134-146.
22. Kyle JL, Harris E. 2008. Global spread and persistence of dengue. Annu. Rev. Microbiol. 62:71-92.
23. Lee CJ, Lin HR, Liao CL, Lin YL. 2008. Cholesterol effectively blocks entry of flavivirus. J. Virol. 82:6470-6480.
24. Liang PH, et al. 2006. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis. Chembiochem 7:165-173.
25. Libraty DH, et al. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185:1213-1221.
26. Libraty DH, et al. 2002. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 186:1165-1168.
27. Miller JL, et al. 2008. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4:e17. doi:10.1371/journal.ppat.0040017.
28. Peiris JS, Porterfield JS. 1979. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282:509-511.
29. Pollock S, et al. 2010. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 24:1866-1878.
30. Pollock S, Dwek RA, Burton DR, Zitzmann N. 2008. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 22:1961-1969.
31. Pollock S, et al. 2010. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc. Natl. Acad. Sci. U. S. A. 107:17176-17181.
32. Puerta-Guardo H, et al. 2010. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains. J. Gen. Virol. 91:394-403.
33. Qu X, et al. 2011. Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob. Agents Chemother. 55:1036-1044.
34. Rawlings AJ, et al. 2009. Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors. Chembiochem 10:1101-1105.
35. Rothwell C, et al. 2009. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389:8-19.
36. Sayce AC, Miller JL, Zitzmann N. 2010. Targeting a host process as an antiviral approach against dengue virus. Trends Microbiol. 18:323-330.
37. Schieffelin JS, et al. 2010. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol. J. 7:28. doi:10.1186/1743-422X-7-28.
38. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195:665-674.
39. Schwendener RA. 2007. Liposomes in biology and medicine. Adv. Exp. Med. Biol. 620:117-128.
40. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
41. Standish K, Kuan G, Aviles W, Balmaseda A, Harris E. 2010. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl. Trop. Dis. 4:e633.
42. Stewart JC. 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104:10-14.
43. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. 2011. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl. Trop. Dis. 5:e1309. doi:10.1371/journal.pntd. 0001309.
44. Vaughn DW, et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
45. Whitby K, et al. 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79:8698-8706.
46. Wichmann O, et al. 2011. Dengue in Thailand and Cambodia: an assessment of the degree of underrecognized disease burden based on reported cases. PLoS Negl. Trop. Dis. 5:e996. doi:10.1371/journal.pntd.0000996.
47. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139.